Health MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation… James Pereira Jul 10, 2023 ROCKVILLE, Md. and PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a… Read More...
Health Iovance Biotherapeutics to Present at Upcoming Conferences James Pereira Apr 24, 2023 <!-- Name:DistributionId Value:8823503 --> <!--… Read More...
Health Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the… James Pereira Apr 19, 2023 <!-- Name:DistributionId Value:8810459 --> <!--… Read More...
Health Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in… James Pereira Mar 30, 2023 <!-- Name:DistributionId Value:8798072 --> <!--… Read More...
Health Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in… James Pereira Mar 25, 2023 <!-- Name:DistributionId Value:8795297 --> <!--… Read More...
Business SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract Nick J Adam Jan 18, 2023 SIOUX FALLS, S.D., Jan. 18, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage… Read More...
Health Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create… James Pereira Jan 9, 2023 -Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million… Read More...
Health SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock James Pereira Dec 8, 2022 SIOUX FALLS, S.D., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage… Read More...
Health Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support… James Pereira Nov 21, 2022 BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company… Read More...
Health Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at… James Pereira Nov 10, 2022 31% Objective Response Rate (ORR) and Median Duration of Response (mDOR) Not Reached at 36.5 Months Median Study Follow… Read More...